(Formerly known as Earum Pharmaceuticals Limited)

CIN: L24230GJ2012PLC071299 Regd. Office: S.F. Shop – 3/2/B Samruddhi Residency, Raspan Arcade, Cross Road, Nr. Satyam Complex, Nikol, Ahmedabad – 382 350 E-mail:<u>earumpharma@gmail.com</u> Website: <u>www.earumpharma.com</u>

Date: 9th December, 2023

To, **BSE India Limited** Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001

Dear Sir / Madam,

Sub: Submission of Unaudited Financial Results for the Quarter and Half Year ended on 30th September, 2023 along with Limited Review Report Ref: Security Id: EARUM / Code: 542724

In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Unaudited Financial Results for the Quarter and Half Year ended on 30th September, 2023 along with Limited Review Report.

Kindly take the same on your record and oblige us.

Thanking You.

For, Murae Organisor Limited (Formerly known as Earum Pharmaceuticals Limited)

Vijaykumar Patel Managing Director DIN: 08073622

(formally know as Earum Pharmaceuticals Ltd)

CIN: L24230GJ2012PLC071299

Registered Office: S.F. Shop – 3/2/B Samruddhi Residency Raspan Arcade Cross Road, Nr. Satyam Complex Nikol Ahmedabad- 382 350

_		(Rs. Ir					
	Particulars		Quarter Ended		Half Year Ended		For The Year
		30-09-2023	30-06-2023	30-09-2022	30-09-2023	30-09-2022	31-03-2023
	ate of start of reporting period	01-07-2023	01-04-2023	01-07-2022	01-04-2023	01-04-2022	01-04-2022
	ate of end of reporting period	30-09-2023	30-06-2023	30-09-2022	30-09-2023	30-09-2022	31-03-2023
	/hether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	evenue From Operations						
) Revenue From Operations	42.86	171.31	711.44	214.17	1,139.31	1,40
()) Other Income	(0.01)	65.90	-	65.89	86.57	22
T	otal Revenue from operations (net)	42.85	237.21	711.44	280.06	1,225.88	1,63
-		12100	207122	/	200100	1,220,000	2,00
Ex	xpenditure						
_) Cost of materials consumed	-	-	-	-	-	
) Purchases of stock-in-trade	56.43	157.37	665.44	213.80	1,081.10	1,31
(c) Changes in inventories of finished goods, work-in- progress and stock-	25.76	72 12	35.04	107.99	02.45	(0)
in	-trade	35.76	72.12	35.04	107.88	92.45	(8
(d	I) Employee benefit expense	1.61	2.16	0.30	3.77	0.48	
) Finance Costs	1.00	25.67	-	26.67	-	2
	e) Depreciation and amortisation expense	1.97	1.97	2.46	3.94	4.84	1
(f)) Other Expenses	43.93	5.94	4.53	49.87	7.04	8
-							
	otal expenses	140.70	265.23	707.77	405.93	1,185.91	1,3
Pr	rofit (loss) Before exceptional & Extraordinary items and Tax	(97.85)	(28.02)	3.67	(125.87)	39.97	27
Ex	cceptional items						
	rofit (loss) from ordinary activities before tax	(97.85)	(28.02)	3.67	(125.87)	39.97	2
	ax Expenses - Current Tax	(10.74)	-	-	(10.74)	-	į
	ess):- MAT Credit	-	-	-		-	
Cu	urrent Tax Expense Relating to Prior years	-	-	-		-	
De	eferred Tax (Assets)/llabtlltles		-	-	-	-	
Pr	rofit (loss) from ordinary activities	(87.11)	(28.02)	3.67	(115.13)	39.97	19
0	ther Comprehensive Income (OCI)						
Ite	ems that will not be reclassified to profit or loss	-	-	-	-	-	
		-	-	-	-	-	
	ems that will be reclassified to profit or loss	-	-	-	-	-	
In	come tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	
_		((22.22)		(
	otal Profit After Other Comprehensive Income	(87.11)	(28.02)	3.67	(115.13)	39.97	19
	rofit/(Loss) From Discountinuing Operation Before Tax ax Expenses of Discontinuing Operations				-		
					-		
	et Profit/(Loss) from Discountinuing Opration After Tax	-	-	-	-	-	
Pr	rofit(Loss) For Period Before Minority Interest	-	-	-	-	-	
Sh	nare Of Profit / Loss Associates	-	-	-	-	-	
Pr	rofit/Loss Of Minority Interset	-	-	-	-	-	
N	et Profit (+)/ Loss (-) For the Period	(87.11)	(28.02)	3.67	(115.13)	39.97	19
De	etails of equity share capital						
	aid-up equity share capital	4,942.23	4,942.23	1,233.58	1,233.58	1,233.58	1,23
Fa	ace value of equity share capital (per share)	2.00	2.00	2.00	2.00	2.00	
	eserve Excluding Revaluation Reserves As Par Balance sheet Of previous	_	-	-			
	ear						
	arnings per share (EPS)						
	asic earnings per share from countinuing And Discountinuing	(0.04)	(0.03)	0.01	(0.16)	0.06	
_	perations	. ,					
	iluted earnings per share from countinuing And Discountinuing	(0.04)	(0.03)	0.01	(0.16)	0.06	
tes:-	perations		-		-		
les	·						
1 Tł	he above said finanical results were reviewed by the Audit Committee and t	then approved by the	Board of Directors	at their respective	Meetings held on	09th December, 2	023.
_							
2 Th	he Statutory Auditors have carried out limited review of the Unaudited Resu	ults of the Compnav fo	or the Quarter and	Half year ended 30)/09/2023.		
	hese results have been prepared in accordance with the Indian Account			34 - Interim Fina	ncial Reporting p	rescribed under Se	ection 133 o
	ompanies Act, 2013 read with Companies (Indian Accounting Standards) Ru	les as amended from	time to time.				
Co							
	he Company has one single segment i.e. Pharmaceuticals Trading Hence, se	parate information fo	r segment wise dis	closure is given in	accordance with t	he requirements o	f Ind AS (AS

5 During the year company has issued the 24,67,16,400 right share at price of Rs. 2/- per share. The effect of right issue has been incoporate in the EPS of pervious year as per the Ind AS 33 "Earning per shares" and restated the same.

6 Statement of Assets and Liabilities and cashflow statement as on 30th September 2023 is enclosed herewith.

7 The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

For, Murae Organisor Limied

Vijaykumar B. Patel Managing Director DIN: 08073622

(formally know as Earum Pharmaceuticals Ltd)

CIN: L24230GJ2012PLC071299

Registered Office: S.F. Shop – 3/2/B Samruddhi Residency Raspan Arcade Cross Road, Nr. Satyam Complex Nikol Ahmedabad- 382 350

Statement of Unaudited Assets and Liabilities as on 30th September,2023

		(Rs. In Lakh)			
	Particulars	Year Ended			
	Data of start of second in a sign	30-09-2023	31-03-2023		
A	Date of start of reporting period	01-04-2023	01-04-2022		
B	Date of end of reporting period	30-09-2023	31-03-2023		
С	Whether results are audited or unaudited	Unaudited	Audited		
	ASSETS				
1	Non-current assets				
a)	Property, Plant and Equipment	43.74	47.68		
b)	Capital work-in-progress				
c)	Investment Property				
d)	Goodwill				
e)	Other Intangible assets	-	-		
f)	Intangible assets under development				
g)	Biological Assets other than bearer plants				
h)	Investments accounted for using equity method				
i)	Financial Assets				
	Investments				
(ii)	Trade receivables				
(iii)	Loans	-	-		
(iv)	Security Deposits				
i)	Deferred tax assets (net)	9.67	-		
j)	Other non-current assets				
2	Current assets				
a)	Inventories	1,205.45	1,313.34		
b)	Financial Assets	-	-		
(i)	Investments	-	-		
	Trade receivables	1,180.35	839.01		
(/	Cash and cash equivalents	1.99	2.52		
	Bank balances other than Cash and cash equivalents	-	-		
	Short Term Loans & Advances	85.99	295.14		
	Others	05.55	255.14		
c)	Current Tax Assets (Net)				
d)	Other current assets	3,524.04	360.66		
3	Non-current assets classified as held for sale	3,524.04	500.00		
4	Regulatory deferral account debit balances and related deferred tax				
4	Total Assets	6,051.23	2,858.35		
	EQUITY & LIABILITIES:	0,051.25	2,058.55		
	Equity				
a)	Equity Share capital	4,942.23	1,233.58		
b)	Other Equity	521.94	637.07		
D)	Liabilities	521.94	037.07		
1)	Non-Current Liabilities				
1)					
a)	Financial Liabilities				
(i)	Long Term Borrowings		-		
(ii)	Trade payables				
(iii)	Other financial liabilities (other than those specified in item (b), to be specified)				
b)	Provisions				
c)	Deferred tax liabilities (Net)	-	1.07		
d)	Deferred government grants (non current)				
e)	Other non-current liabilities				
2)	Current liabilities				
a)	Financial Liabilities				
(i)	Short Term Borrowings	251.58	873.99		
(ii)	Trade payables				
	Total Outstanding Dues of creditors micro and small enterprise	111.77	(23.72)		
	Total Outstanding Dues of creditors other than micro and small		· ·		
	enterprise	17.09	(61.54)		
(iii)	Other financial liabilities				
a)	Provisions	55.30	29.64		
b)	Income/Current Tax Liabilities (Net)	153.09	160.13		
c)	Other current liabilities	(1.77)	8.13		
<i>c</i> ₁	Total Liabilities	6,051.23	2,858.35		
		0,051.23	2,030.35		

For, Murae Organisor Limied

Vijaykumar B. Patel Managing Director DIN: 08073622

Date :- 09-12-2023 Place :- Ahmedabad

(formally know as Earum Pharmaceuticals Ltd)

CIN: L24230GJ2012PLC071299

Registered Office: S.F. Shop – 3/2/B Samruddhi Residency Raspan Arcade Cross Road, Nr. Satyam Complex Nikol Ahmedabad- 382 350

Unaudited Cash Flow Statement for the half year ended September 30, 2023 As on As on Particulars 30th September, 2023 30th September, 2022 Rs. In Lakhs Rs. In Lakhs A. Cash flow from operating activities Profit before Tax -125.87 39.97 Adjustments for: Depreciation and amortisation 3.94 4.84 Finance costs 26.67 Operating profit / (loss) before working capital changes -95.26 44.81 Movements in Working Capital (Increase) / Decrease Inventories 107.89 92.47 209.15 (110.37) (Increase) / Decrease Short-term loans and advances 214.12 Increase / (Decrease) Trade payables (36.07) (Increase) / Decrease Trade Receivables (341.34) (14.02) Increase / (Decrease) Short Term Provisions 25.66 Increase / (Decrease) Other current Assets (3,163.38) . Increase / (Decrease) Other current liabilities (9.90) 47.86 Net Cash Generated/(Used in) Operations -2,957.80 -20.13 Direct Taxes Paid including for past years (7.04) Net cash flow from / (used in) operating activities (A) -3,060.10 24.68 B. Cash flow from Investing activities Sale of Fixed Assets Net cash flow from / (used in) investing activities (B) 0.00 0.00 C. Cash flow from financing activities Finance cost -26.67 Increase / (Decrease) Long Term Borrowings 0.00 -Proceeds From Issue of Share Capital 3,708.65 -Increase / (Decrease) Short Term Borrowings -622.41 Net cash flow from / (used in) financing activities (C) 3,059.58 0.00 Net increase / (decrease) in Cash and cash equivalents (A+B+C) 24.68 -0.53 Cash and cash equivalents at the beginning of the year 2.52 5.30 Cash and cash equivalents at the end of the year * 1.99 29.98 * Comprises: 4.41 (a) Cash on hand 1.99 (b) Balances with banks 25.57 (i) In current accounts (ii) In deposit accounts 1.99 29.98

For, Murae Organisor Limied

Date :- 09-12-2023 Place :- Ahmedabad Vijaykumar B. Patel Managing Director DIN: 08073622



Chartered Accountants

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED

Review Report to The Board of Directors MURAE ORGANISOR LIMITED

We have reviewed the accompanying statement of unaudited financial results of **MURAE ORGANISOR LIMITED** (the "Company") for the quarter ended September 30, 2023 and year to date from April 01, 2023, to September 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to

Head Office :	217/218/219, Manek Center, P.N. Marg, Jamnagar - 361008.
	Cell: 91 98242 31214 Ph.: 0288 2661942 Email: dgmsco.jam@gmail.com
Branch Office :	Shop No. F-04A, 1st Floor, Eternity Mall, Naupada, Teen Haath Naka, LBS Marg, Eastern Express Highway, Thane West - 400604.



whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') ·specified under Section 133 of the Companies -Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, D G M S & Co. Chartered Accountants

Shashank P. Doshi Partner Membership No. 108456 FRN: 0112287W Date: 09-12-2023 Place: Jamnagar UDIN: 23108456BGUEDR4208

Head Office :217/218/219, Manek Center, P.N. Marg, Jamnagar - 361008.
Cell: 91 98242 31214 Ph.: 0288 2661942 Email: dgmsco.jam@gmail.comBranch Office :Shop No. F-04A, 1st Floor, Eternity Mall, Naupada, Teen Haath Naka, LBS Marg,
Eastern Express Highway, Thane West - 400604.